A PYMNTS Company

Ireland/US: Generic drugmaker Mylan offers $29 billion for Perrigo

By  |  April 9, 2015

In what could turn out to be its largest acquisition ever, generic drug giant Mylan on Wednesday went public with a bid for competing Ireland-based drugmaker Perrigo Co. in a deal valued at about $30 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The proposal, offering $205 a share in an unspecified combination of cash and stock, was contained in a letter from Mylan chairman Robert Coury delivered to Perrigo CEO Joseph Papa on Monday. Mylan released the letter Wednesday morning.

    Mr. Coury’s letter indicated that joining forces with Perrigo would nearly double Mylan’s revenue, which was $7.7 billion in 2014.

    Perrigo, based in Dublin, issued a brief statement Wednesday afternoon acknowledging the “unsolicited” proposal, saying, “The board of Perrigo will meet to discuss the proposal and a further announcement will be made when appropriate.”

     

    Full Content: The New York Times

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.